So we think that this window of opportunity neoadjuvant platform is really promising for testing novel therapies. We have been able to establish organoids, patient-derived xenografts, we have circulating tumor DNA (ctDNA), we have urine cell-free DNA, and we have analyzed all of that and we’re continuing to analyze this data. It gives us really a wealth of information and understanding of the biology that helps us understand the effects of the drug and test novel therapies or novel therapy combinations in this clinical setting...
So we think that this window of opportunity neoadjuvant platform is really promising for testing novel therapies. We have been able to establish organoids, patient-derived xenografts, we have circulating tumor DNA (ctDNA), we have urine cell-free DNA, and we have analyzed all of that and we’re continuing to analyze this data. It gives us really a wealth of information and understanding of the biology that helps us understand the effects of the drug and test novel therapies or novel therapy combinations in this clinical setting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
